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ORIGINAL RESEARCH
Formulating a Treatment Plan in
Suspected Lymphoma
Ultrasound-Guided Core Needle Biopsy Versus Core Needle
Biopsy and Fine-Needle Aspiration of Peripheral Lymph Nodes
Monica R. Drylewicz, MD, PhD , Marcus P. Watkins, PhD, Anup S. Shetty, MD, Michael F. Lin, MD,
Amber Salter, PhD, Nancy L. Bartlett, MD, William D. Middleton, MD, Motoyo Yano, MD, PhD
Objectives—Image-guided tissue sampling in the workup of suspected lym-
phoma can be performed by core needle biopsy (CNB) or CNB with fine-needle
aspiration (FNA). We compared the yield of clinically actionable diagnoses
between these methods of tissue sampling.
Methods—All ultrasound-guided percutaneous peripheral lymph node biopsies from
2010 to 2017 at a single institution were retrospectively reviewed for biopsy type
(CNB versus CNB + FNA), prior diagnosis of lymphoma, size of the target lymph
node, number of cores, length of core specimens, and pathologic diagnosis. Lym-
phoma and lymphoid tissue were included; metastatic disease and nonlymphoid tis-
sue were excluded. An oncologist specializing in lymphoma independently
determined whether an actionable diagnosis could be made with the pathologic
results in the context of the patient’s medical record. χ2 analyses and univariable/
multivariable logistic regression models were used for statistical analyses.
Results—Of 578 lymph node biopsies, 306 (53%) had a prior diagnosis of lym-
phoma; 273 (47%) were CNB, and 305 (53%) were CNB + FNA. There was
no significant difference between biopsy types (CNB versus CNB + FNA) in
the number of cores (median [25th, 75th percentiles], 3 [3, 4] versus 4 [3, 4];
P = .47) or total length of tissue (4.1 [2.5, 6.1] versus 3.7 [2.3, 6] cm; P = .09).
There was no difference in obtaining an actionable diagnosis between biopsy
types after controlling for a known history of lymphoma (P = .271) or after con-
trolling for the number of core specimens (P = .826).
Conclusions—In cases of suspected lymphoma, CNB without FNA was sufficient
to obtain an actionable diagnosis.
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L
ymphoma is a broad category of diseases encompassing
malignancies of the lymphocyte (B cells and T cells). There
are more than 50 different subtypes of lymphoma in the most
recent classification system,1 the treatment and prognosis of which vary
considerably. Patients may present with vague symptoms such as low-
grade fever and weight loss, palpable lymphadenopathy, or altered
hematologic laboratory values. The diagnostic evaluation for lympho-
ma requires tissue for determination of the presence of lymphoma and
disease subclassification to formulate a treatment plan.1
Multiple methods may be used to obtain tissue for histopatho-
logic analysis, including excisional/incisional biopsy and image-guided
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percutaneous tissue sampling by core needle biopsy
(CNB) or fine-needle aspiration (FNA).2,3 Although
there is no clear recommendation by the American Can-
cer Society as of 2016, the European Society of Medical
Oncology recommends surgical excision whenever pos-
sible.4 However, in our experience, many physicians,
including those with expertise in lymphoma, prefer per-
cutaneous biopsy given its less-invasive nature, ease of
scheduling, lower cost, and generally high yield of diag-
nostic data. Core needle biopsy uses a spring-loaded
side notch or hollow-bore needle to obtain a solid core
of tissue from the target lesion. Fine-needle aspiration
uses multiple small-gauge needles with rapid back-and-
forth motion in the target lesion to collect individual
cells in the needle tip. Core biopsies, when intact, retain
some architectural context, whereas FNA loses all such
tissue information, relying solely on individual cellular
characteristics for diagnosis.5
There is a large volume of literature investigating
the diagnostic yield of tissue sampling in the setting
of suspected lymphoma. Many of these studies have
addressed whether image-guided biopsy performs
adequately compared to excisional biopsy in the diag-
nosis and treatment of lymphoma.4,6–8 Fine-needle
aspiration alone is clearly inadequate compared to
excisional biopsy.2,9 The success rate of CNB alone in
yielding a clinically actionable diagnosis ranges from
67% to 100%.6,7,10–18 Some of the highest yields con-
sidered only patients with a history of lymphoma
(90%–97%)7,10,13 or reported the success rate of sub-
classification when lymphoma was diagnosed on the
biopsy (100%).12 In our practice, CNB and FNA of
the same target lesion are often requested and per-
formed to collect tissue for histopathologic analysis
and flow cytometry. However, performing both CNB
and FNA increases the procedural time as well as cost
and, potentially, patient anxiety. We performed this
study given the paucity of data comparing the action-
able yield of CNB compared to CNB + FNA.
Materials and Methods
A cohort of patients with lymphadenopathy biopsied
with ultrasound guidance at our institution between
July 1, 2010 and December 31, 2016, was retrospec-
tively reviewed. The patient cohort was obtained by a
Health Insurance Portability and Accountability Act–
compliant, Institutional Review Board–approved
search of our institutional radiology database, Mon-
tage (Nuance Communications, Burlington, MA).
Informed consent was waived by the Institutional
Review Board. Biopsy of superficial lymphadenopathy
was performed by searching for studies given a Cur-
rent Procedural Terminology code for needle biopsy of
lymph nodes (code 38505) exclusive of breast.
Excluding the term “breast” was done to eliminate
the large number of axillary lymph node biopsies per-
formed to diagnose metastatic breast cancer. For
patients with multiple biopsies, whether it be on the
same or different dates, only the first biopsy per-
formed was included for analysis. Therefore, each
biopsy corresponded to an individual patient. Biopsies
performed for research, those without a final pathol-
ogy report, those coded incorrectly, and those yield-
ing a diagnosis of metastasis, another mass, or no
lymphoid tissue were excluded.
Several data points were collected for each biopsy
and are detailed in Table 1. These data points included
patient sex, age, date of biopsy, whether the patient had
a prior diagnosis of lymphoma, location of the biopsy,
largest dimension of the target lesion, type of biopsy
performed (CNB or CNB + FNA), CNB gauge, and
number of CNB passes. Core needle biopsy specimens
were placed in formalin and submitted to surgical
pathology for interpretation. Fine-needle aspiration
specimens were submitted in RPMI solution for flow
cytometry with the assistance of our sonographers. No
pathologist was present at the time of CNB or FNA.
Reported complications of the procedure were
recorded. Minimum and maximum lengths of the core
samples received by pathology and the pathologic diag-
nosis were recorded. The total length of CNB tissue
was estimated as follows: [(number of cores –
1) × maximum core length recorded by pathology] +
minimum core length recorded by pathology.
The hematology/oncology team specializing in
lymphoma then independently reviewed the pathologic
diagnosis as well as other available data from the
patient’s medical record. A binary decision was ren-
dered, determining whether the diagnosis was action-
able. A diagnosis was considered actionable if the
pathologic diagnosis considered within the context of
the patient allowed either for initiation of treatment or
final determination of benignity requiring no further
intervention.
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Descriptive statistics were used to summarize
patient and biopsy characteristics using medians [25th,
75th percentiles] for continuous variables and fre-
quency (percent) for categorical variables. Differences
in characteristics and actionable diagnoses between
CNB and CNB + FNA were compared by Wilcoxon
rank sum or χ2 square tests as appropriate. A Cochran-
Mantel-Haenszel test was used to evaluate the associa-
tion of an actionable diagnosis and biopsy controlling
for a history of lymphoma. The association between
the number of cores and target size was evaluated by a
Spearman correlation. Multivariable logistic regression
models were used to evaluate the association of the
number of cores and CNB gauge with an actionable
diagnosis. Statistical analyses were performed with SAS
version 9.4 software (SAS Institute Inc, Cary, NC).
Results
The initial search yielded 908 superficial lymph node
biopsies performed with ultrasound guidance. A total
of 25 biopsies were performed for research; 13 were
incorrectly coded; and 12 were missing pathologic
results. A total of 858 biopsies were analyzed:
259 yielded metastatic disease; 6 yielded a diagnosis
of another mass (1 Warthin tumor, 3 peripheral nerve
sheath tumors, 1 myoepithelial cyst, and 1 lymphoe-
pithelial cyst); and 15 showed no lymphoid tissue
(generally showing necrosis or muscle on pathologic
specimens). These were excluded from the analysis. A
total of 578 biopsies yielded a diagnosis of lymphoma
or benign/indeterminate lymphoid tissue and were
further analyzed by our oncology team.
Of the 578 biopsies used for analysis, 273 were
CNB, and 305 were CNB + FNA (Table 1). These
patient populations were similar in sex distribution
(58.6% versus 53.4% male, respectively). Patients under-
going CNB alone were significantly older than patients
undergoing CNB + FNA (62 [49, 70] versus
54 [39, 65] years, respectively; P < .01). When compar-
ing the proportion of patients with a history of lym-
phoma between the biopsy types, more patients
undergoing CNB alone had a prior diagnosis of lym-
phoma compared to those undergoing CNB + FNA
(76.9% versus 31.8%; P < .01). Biopsied peripheral
lymph node locations were cervical/supraclavicular
(34.8% of CNB versus 49.2% of CNB + FNA), inguinal
(31.5% of CNB versus 26.9% of CNB + FNA), and
axillary (30.8% of CNB versus 22.0% of CNB + FNA).
Most CNB specimens were obtained with an 18-gauge
needle. There was no difference in the median [25th,
75th percentiles] number of cores (3 [3, 4] versus
4 [3, 4]; P = .47), estimated length of CNB tissue (4.1
[2.5, 6.1] versus 3.7 [2.3, 6.0] cm; P = .09), or target
size (3.3 [2.2, 4.1] versus 3.2 [2.1, 4.0] cm; P = .5;
Figure 1) between biopsy types. There was no associa-
tion between the target size and the number of core
specimens obtained (r = 0.08; Figure 2).
The proportion of actionable diagnoses with CNB
alone was greater than that with CNB + FNA (83.5%
versus 71.5%; Table 2). However, after controlling for a
history of lymphoma, there was no significant difference
in obtaining an actionable diagnosis between CNB ver-
sus CNB + FNA (P = .271; Table 3). There was no
significant association between achievement of an
Table 1. Patient and Biopsy Statistics
Variable CNB CNB + FNA P
Patients, n 273 305





Sex, n (%) .212
Male 160 (58.6) 163 (53.4)




No 63 (23.1) 208 (68.2)
Yes 210 (76.9) 97 (31.8)
Biopsy location, n (%) .0008
Cervical/
supraclavicular
95 (34.8) 150 (49.2)
Inguinal 86 (31.5) 82 (26.9)
Axillary 84 (30.8) 67 (22.0)








CNB gauge, n (%) .889
16 19 (6.9) 21 (6.8)
18 253 (92.7) 282 (92.4)
20 1 (0.4) 2 (0.6)
Cores, n (%)
1–2 67 (24.5) 61 (20.0)
3 79 (28.9) 88 (28.8)
4 60 (22.0) 111 (36.4)
≥5 67 (24.5) 45 (14.8)
Cores, n 3 [3, 4] (1–8) 4 [3, 4] (1–7) .47





Data are presented as median [25th, 75th percentiles] (range)
where applicable. Statistical significance was determined by the
Wilcoxon rank sum test for continuous variables and the χ2 test for
categorical variables.
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actionable diagnosis and the number of cores
(P = .826) or needle gauge (P = .172, 18 versus
16 gauge; and P = .088, 18 versus 20 gauge).
Of the 578 biopsies, only 3 minor complications
were documented: 2 small hematomas (18-gauge
CNB) and 1 case of left-hand numbness (18-gauge
CNB + FNA), which resolved, presumed related to
lidocaine infiltration of the axillary nerve. These find-
ings correspond to a minor complication rate of 0.5%,
with no major complications.
Discussion
The data from this retrospective study demonstrate
that CNB alone performs as well as CNB + FNA in
achieving an actionable diagnosis, after controlling for
a history of lymphoma. Our study reflects clinical
work flow, as the oncologist made the determination
of whether an actionable diagnosis was achieved
through biopsy and pathologic diagnosis, and differs
from other diagnostic yield investigations, which use
lymphoma subclassification as the end
point.7,10,12–14,18,19 This approach is likely more clini-
cally relevant, as the pathologic diagnosis is inter-
preted within the context of an individual patient. For
example, there may be high clinical suspicion for
transformation of a previously subclassified lym-
phoma, which is not reflected in the pathologic speci-
men because of a sampling error. In our study, this
discrepancy would be classified as not achieving an
actionable diagnosis, whereas if subclassification were
the end point, it would be categorized as a successful
case. Because of these differences in study methods,
our results are not directly comparable to other
studies.
Our study demonstrated a greater yield of action-
able diagnoses in patients with a history of lymphoma
(82.4%–88.1%) as opposed to those without a known
history (66.4%–68.2%), consistent with the
literature.7,10,13
In our comparison of CNB to CNB + FNA, we
found that the mean age of patients undergoing CNB
Figure 1. Box plot of target size by biopsy type. Boxes represent
the 25th and 75th percentiles, with horizontal lines within the boxes
representing the medians, and lines extending from the boxes indi-
cating the minimum and maximum values. There is no difference in
the size of the targeted lymph node between CNB and
CNB + FNA.
Figure 2. Number of cores obtained by target size. Boxes repre-
sent the 25th and 75th percentiles, with vertical lines within the
boxes representing the medians, and lines extending from the
boxes indicating the minimum and maximum values. The graph
shows the distribution of the number of cores obtained by either
CNB or CNB + FNA based on the size of the targeted lymph node.
There is no correlation between the number of cores of obtained
and the size of the targeted lymph node (r = 0.08).
Table 2. Actionable Diagnosis by Biopsy Type
Actionable Diagnosis CNB CNB + FNA Total P
No, n (%) 45 (16.5) 87 (28.5) 132
Yes, n (%) 228 (83.5) 218 (71.5) 446
Total, n 273 305 578 .0006
Statistical significance was determined by the χ2 test.
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alone was older than that of those undergoing
CNB + FNA. We also found that patients with a his-
tory of lymphoma were more likely to undergo CNB
alone rather than CNB + FNA. These findings are
consistent with our institutional practice of perform-
ing CNB + FNA rather than CNB alone for new
potential diagnoses of lymphoma in which patients
are often younger than those with established diagno-
ses who have recurrent disease after treatment.
We found that the number of core specimens
obtained did not affect the actionable yield. This finding
seems counterintuitive given the general propensity of
pathologists to desire more tissue. Given the retrospec-
tive nature of this study, it is difficult to determine with
certainty the reason why more tissue did not result in a
greater yield. The pathology and radiology reports did
not specify the total length of tissue obtained, and it is
possible that our core length estimations were incorrect,
especially if the core specimens were highly fragmented,
a data point that was not available in the radiology
report. However, the number of cores submitted also
did not affect the actionable yield. As the number of
cores obtained was at the discretion of the performing
radiologist, it is possible that more core specimens were
obtained by the radiologist when the core specimens
were fragmented, of a shorter length, or otherwise
thought to be of low quality. It is also possible that
pathologist satisfaction with fewer cores or the method
used by pathology in the review of specimens negated
the impact of a greater number of cores.
Although the large population size is a major
strength of our study, there were several limitations.
First, because of its retrospective design, data points
pertaining to the length and quality of cores were
inaccessible. Second, this study was limited to periph-
eral lymph nodes and may not necessarily apply to
deeper locations such as retroperitoneal lymph nodes,
sampled under computed tomographic guidance.
Third, the calculated yield of actionable diagnoses did
not include failed procedures meant to sample lym-
phoid tissue, and inclusion of these cases may have
decreased our overall yield but would apply to both
methods of tissue sampling. In fact, no case was
found in which FNA obtained an actionable diagnosis
when the CNB showed no lymphoid tissue.
In patients with a suspected new diagnosis of lym-
phoma, current practice at our institution is to perform
CNB and FNA concurrently, whereas in cases with a
history of lymphoma, CNB is performed, with or with-
out FNA, at the discretion of the ordering physician and
radiologist. In both groups of patients, performing CNB
alone may decrease the procedure time and cost, poten-
tially leading to improved patient satisfaction while
maintaining a similar diagnostic yield.
Core needle biopsy without FNA of peripheral
lymph nodes provides sufficient tissue to obtain an
actionable diagnosis in new or recurrent lymphoma.
However, discussions with our pathologists reveal
that flow cytometric data from FNA may decrease the
special stains necessary for processing of CNB speci-
mens, potentially improving pathology work flow.
Our institutional practice is to submit FNA for flow
cytometry, but CNB specimens in RPMI solution
could be submitted for this purpose, streamlining the
work flow for both pathology and radiology.
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